Several promising molecular targets have been identified, including mutant IDH, PDGFR, VEGFR, integrin αvβ3 receptor, EGFR, c-Met, etc., These molecules and their specific inhibitors have been studied in multiple trials, and we summarize the MI modalities that are being used to visualize them in the context of glioma therapy. This evidence concerns the gene PDGFRB and central nervous system cancer.